$PROG $KDMN getting bought out at about 2x market cap by Sanofi for their recently approved graft vs host disease drug. A quick search shows a global market opportunity of about $650million in the next few years. $PROG Preecludia asset for preeclampsia is launching end of this year in a US $2+bil market. About 62% of shares held by a hedge fund, 12% by the CEO. Over 90% of shares locked up. CEO just resigned. Oh yea I'm bullish.
2
9
9 Likes